Anaphylaxis in Mastocytosis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
An increase in anaphylaxis has been reported in mastocytosis, with a predominance of males. Recurrent idiopathic anaphylaxis and either hymenoptera-venom or drug-induced anaphylaxis are the most frequent types of anaphylaxis, no correlation being found between the signs and symptoms of anaphylaxis and MC burden or serum tryptase levels. Less frequently, anaphylaxis can occur during general anesthesia, and other invasive and therapeutic procedures, indicating that appropriate management of SM patients before, during, and after these procedures is required. Venom immunotherapy (VIT) has proved to be effective in mastocytosis, but adverse reactions have also been reported in 10–15% of the patients and fatal reactions have been described after discontinuation of venom immunotherapy. Therapeutic measures of anaphylaxis in mastocytosis should include: (1) adequate information and training of patients, their relatives, and care providers, (2) availability of individual emergency kits, (3) avoidance of triggering factors, and (4) administration of preventive medication prior to anesthesia and other therapeutic procedures. Additionally, specific treatment of anaphylaxis should be carefully evaluated in each individual patient. Prompt recognition and appropriate control of the acute episodes together with a decrease in the frequency and intensity of chronic symptoms should be attempted with antimediator therapy (e.g. sedating and nonsedating H1 antihistamines and other NSAIDs, oral disodium cromolyn or, in selected cases, aspirin). Steroids should be used in selected cases. Interferon-alpha, hydroxyurea, cytoreductive therapy with cladribine, and omalizumab anti-IgE monoclonal antibody therapy might be of benefit in selected refractory cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256 · cited 1×
“Adverse reactions to venom immunotherapy (VIT), including anaphylaxis, in 12% of the cases have been reported [62] (reviewed in reference [63]).”
BackgroundBrockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Bonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
Epidemiology of life-threatening and lethal anaphylaxis: a review
Moneret‐Vautrin, D. A., Morisset, M., Flabbee, J., Beaudouin, E., & Kanny, G. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00785.x · Cited by 386 · cited 1×
“5 cases per 100,000 individuals/year [47–49].”
González de Olano, D., De La Hoz Caballer, B., Núñez López, R., Sánchez Muñoz, L., Cuevas Agustín, M., Diéguez, M. C., Álvarez Twose, I., Castells, M. C., & Escribano Mora, L. (2007) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2007.02804.x · Cited by 245 · cited 14×
“In two other studies in large series of cases including 210 [34] and 120 [35] patients with mastocytosis, the percentage of allergy among adult patients and children was of 23.”
BackgroundInfluentialAkin, C., Scott, L. M., Kocabas, C. N., Kushnir-Sukhov, N., Brittain, E., Noel, P., & Metcalfe, D. D. (2007) · Blood · doi:10.1182/blood-2006-06-028100 · Cited by 240
Oude Elberink, J. N. G., de Monchy, J. G. R., Kors, J. W., van Doormaal, J. J., & Dubois, A. E. J. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)81058-5 · Cited by 203
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172 · cited 1×
“Omalizumab has proven to be effective in the treatment of three patients with mastocytosis, elevated total and specific IgE and recurrent anaphylaxis refractory to intensive antimediator therapy [117].”
BackgroundSonneck, K., Florian, S., Müllauer, L., Wimazal, F., Födinger, M., Sperr, W. R., & Valent, P. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000096442 · Cited by 129 · cited 3×
“In patients with recurrent anaphylaxis, who present with syncopal or near-syncopal episodes [29, 30] without associated hives or angioedema [31], mastocytosis needs to be ruled out.”
BackgroundHow much specific is the association between hymenoptera venom allergy and mastocytosis?
Bonadonna, P., Zanotti, R., Pagani, M., Caruso, B., Perbellini, O., Colarossi, S., Olivieri, E., Dama, A., Schiappoli, M., Senna, G., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02108.x · Cited by 87 · cited 1×
“[27, 34, 60 ] and mastocytosis is a risk factor for severe reactions in HVA patients [35, 61].”
Cited by
The mastocytosis society survey on mast cell disorders: patient experiences and perceptions
Jennings, S., Russell, N., Jennings, B., Slee, V., Sterling, L., Castells, M., Valent, P., & Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2013.09.004 · Cited by 143
Schuch, A., & Brockow, K. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.017 · Cited by 88
Anaphylaxis as a clinical manifestation of clonal mast cell disorders
Matito, A., Alvarez-Twose, I., Morgado, J. M., Sánchez-Muñoz, L., Orfao, A., & Escribano, L. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0450-8 · Cited by 51
Self-citationCutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?
Matito, A., & Carter, M. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0525-1 · Cited by 39
Metadata
- Authors
- Escribano, L., & Orfao, A.
- Venue
- Anaphylaxis and Hypersensitivity Reactions
- Publisher
- Humana Press
- Published
- 2010-11-19
- Pages
- 257-269
- OpenAlex
- W2207659374
- Cited by
- 7
- References
- 12
- FWCI
- 0.45
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anaphylaxis in Mastocytosis. https://app.cochat.ai/papers/10.1007/978-1-60327-951-2_16
- The paper
- Escribano, L., & Orfao, A. (2011). Anaphylaxis in Mastocytosis. Anaphylaxis and Hypersensitivity Reactions. https://doi.org/10.1007/978-1-60327-951-2_16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.